Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Acute Ischemic Stroke Drugs Industry?

The market for acute ischemic stroke medications has seen consistent growth over the past few years. The market is set to expand from $13.5 billion in 2024 to $14.07 billion in 2025, achieving a compound annual growth rate (CAGR) of 4.3%. Factors contributing to this growth in the historic period include the rising occurrence of stroke, government-backed initiatives and healthcare schemes, enhanced awareness and education, strategic alliances and partnerships, and an aging population.

In the upcoming years, the market size for acute ischemic stroke drugs is anticipated to witness robust growth. It is projected to escalate to “$17.62 billion in 2029 with a compound annual growth rate (CAGR) of 5.8%.” The upward trend during the forecast period can be credited to the emergence of new therapies and drug pipeline, precision medicine and personalized therapies, development in the worldwide healthcare infrastructure, rise in healthcare expenditure, and the advent of telemedicine and remote patient monitoring. Key trends expected during the forecast period include progress in thrombolytic therapies, development of neuroprotective agents, personalized medicine and biomarker research, the growth of telemedicine and remote monitoring, along with collaborations and strategic alliances.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10049&type=smp

#Which Factors Are Currently Driving The Growth Of The Acute Ischemic Stroke Drugs Market?

An increase in chronic illnesses is expected to stimulate the expansion of the acute ischemic stroke drug market in the near future. Long-term conditions, also identified as non-communicable illnesses, are disorders that persist for at least a year, needing constant healthcare, or limit day-to-day activities. Major contributors to mortality and disability are chronic diseases such as cardiovascular disease, malignancy, and diabetes. Acute ischemic stroke medications are predominantly utilized in managing these chronic conditions to lower the likelihood of clot creation, strokes, and to reinstate cerebral blood circulation. For example, as per the data provided by the World Health Organization (WHO) in September 2022, a health organization based in Switzerland, about 41 million individuals succumb to chronic diseases annually, constituting 74% of all global fatalities, with 17 million people passing before they reach 70 due to these diseases. By the year 2025, a projected 164 million Americans, roughly equating to 49% of the populace, are expected to be diagnosed with chronic diseases. Consequently, the increasing occurrence of chronic diseases is fuelling the advancement of the acute ischemic stroke drug market.

How Is The Global Acute Ischemic Stroke Drugs Market Structured In Terms Of Segments?

The acute ischemic stroke drugs market covered in this report is segmented –

1) By Type: Tablet, Capsule, Other Types

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Hospitals, Diagnostic Centers, Other Applications

Subsegments:

1) By Tablet: Immediate Release Tablets, Extended Release Tablets, Orally Disintegrating Tablets

2) By Capsule: Hard Shell Capsules, Soft Gelatin Capsules, Extended Release Capsules

3) By Other Types: Injectable Solutions, Intravenous (IV) Preparations, Inhalation Formulations

Which Emerging Trends And Strategic Shifts Are Shaping The Acute Ischemic Stroke Drugs Market?

Leading businesses in the acute ischemic stroke drug market are pioneering new drug formulations including sublingual versions of edaravone and dexborneol specifically for acute ischemic stroke. A medication of this nature, designed to be placed beneath the tongue, ensures rapid absorption into the blood. This combination maximizes both the antioxidant and anti-inflammatory properties of the two compounds, thereby boosting the effectiveness of the treatment. For example, in October 2024, Simcere Pharmaceutical, a pharmaceutical company based in China, achieved breakthrough therapy status for their drug, Sanbexin, a sublingual formulation of edaravone and dexborneol, designed for the treatment of acute ischemic stroke (AIS). This development came on the back of encouraging results from the TASTE-SL phase 3 clinical trial (NCT04950920), which showed that 64.4% of patients given Sanbexin reached a modified Rankin Scale (mRS) score of =1 at 90 days, a improvement on the 54.7% observed in the placebo group. It is anticipated that this treatment method, which can be administered outside of a hospital setting, will reduce disability and result in better outcomes for AIS patients.

Who Are The Main Participants Shaping The Acute Ischemic Stroke Drugs Market Landscape?

Major companies operating in the acute ischemic stroke drugs market include F. Hoffmann-La Roche AG, C.H. Boehringer Sohn AG & Co. KG, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, AstraZeneca plc, ZZ Biotech LLC, NoNO Inc., Biogen Inc., Athersys Inc., Bayer AG, Sanofi S.A., Pfizer Inc., DiaMedica Therapeutics, Lumosa Therapeutics Co. Ltd., Johnson & Johnson, Acticor Biotech, Meridigen Biotech Co., Prolong Pharmaceuticals LLC, Nanjing Yoko Biomedical Co. Ltd., TrueBinding Inc., GNT Pharma Co. Ltd., aptaTargets SL, NuvOX Pharma, Simcere Pharmaceutical Co. Ltd., Genentech Inc., Pharming Technologies B.V., SanBio BV, Revalesio Corporation, Stemedica Cell Technologies Inc., CorInnova Incorporated, Phagenesis

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-drugs-global-market-report

Which Region Currently Holds The Largest Share In The Acute Ischemic Stroke Drugs Market?

North America was the largest region in the acute ischemic stroke drugs market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global acute ischemic stroke drugs market report during the forecast period. The regions covered in the acute ischemic stroke drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10049&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model